PACB executive awarded options and RSUs

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that executive James R. Gibson II received new equity awards.

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that executive James R. Gibson II received new equity awards. He was granted a stock option for 667,696 shares with an exercise price of $0.00 per share, and 333,848 shares of common stock as restricted stock units.

The RSUs will vest in equal annual installments on February 15 of 2027, 2028, and 2029, subject to his continued service. The stock option will vest in 36 equal monthly installments beginning on March 27, 2026, also conditioned on continued service. These are non-cash, compensation-related acquisitions rather than open-market purchases.

Insider Trade Summary

Grant/Award: 1,001,544 shares

Grant/Award 2 txns

Insider Gibson James R II

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	667,696	$0.00	$0.00
Grant/Award	Common Stock	333,848	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 667,696 contracts (Direct); Common Stock — 1,333,848 shares (Direct)

Footnotes (2)

1. F1. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.
2. F2. The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did James R. Gibson II acquire in the latest PACB Form 4?

James R. Gibson II received equity awards consisting of a stock option for 667,696 shares and 333,848 restricted stock units of PACB common stock. Both awards were granted at a per-share price of $0.00 as part of his compensation, not open-market buying.

How do the new PACB restricted stock units for James R. Gibson II vest?

The 333,848 RSUs granted to James R. Gibson II vest in three equal annual installments on February 15 of 2027, 2028, and 2029. Vesting is conditioned on his continued status as a service provider through each applicable vesting date.

What is the vesting schedule of James R. Gibson II’s new PACB stock option?

The stock option covering 667,696 shares vests in 36 equal monthly installments, beginning on March 27, 2026. Each monthly tranche requires that James R. Gibson II remain a service provider through the respective vesting dates to receive those option shares.

Were the PACB equity awards to James R. Gibson II open-market purchases?

No, the PACB transactions are grant or award acquisitions at a price of $0.00 per share, reflecting compensation-related equity grants. They are not open-market purchases and do not involve cash paid by the reporting person for the shares at grant.

How many PACB shares does James R. Gibson II hold after these Form 4 transactions?

After the reported transactions, James R. Gibson II holds 667,696 option shares and 1,333,848 shares of common stock, as indicated by the post-transaction share balances. These holdings include the newly granted awards reported in this Form 4 filing.

What transaction code is used for James R. Gibson II’s PACB equity awards?

Both transactions use code A, described as a Grant, award, or other acquisition. This indicates the shares were awarded as part of compensation, rather than purchased or sold in the open market, and align with standard equity incentive practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:14 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gibson James R II

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		333,848(1)	A	$0	1,333,848	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.68	02/27/2026		A		667,696		(2)	02/27/2036	Common Stock	667,696	$0	667,696	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

2. The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

Remarks:

Chief Financial Officer

	/s/ Michele Farmer, Attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.